Harvard, Tufts med students stage protest at ‘biased’ $2.9B drug development figure

Ben Adams Around two dozen students from Harvard Medical School and Tufts University as well as members of health activist groups protested in front of the Tufts Center for the Study ...

Cipla says top 50 drugs in development could bring in $30B

John Carroll Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $ 30 billion. FierceBiotech ...

Apogenix inks cancer drug development deal for China

John Carroll Germany's Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize ...

J&J awaits jury verdict over Risperdal patient’s breast development

Tracy Staton Did Johnson & Johnson hide Risperdal's potential to trigger breast growth in boys? Or did the drugmaker adequately disclose the potential side effect? A Philadelphia ...

Ebola outbreak rages on as drug development remains slow

Emily Mullin As the death toll from West Africa's Ebola outbreak hits nearly 540–a 60% mortality rate–drug development for the untreatable disease is lagging, largely ...

Industry Voices: The contributions of immunology translational medicine to clinical pharmaceutical development

Alok Saboo Translational medicine, which bridges the science of the emerging preclinical portfolio and the early development space where molecules are studied in humans for the first ...

KGK Synergize Inc. Welcomes Loren Brown As the New Director of Business Development!

barbara.lempert LONDON, ON, OCTOBER 31, 2013 – KGK Synergize Inc., a contract research organization offering human clinical trials to the health nutrition industry, is very pleased ...

Greenphire Appoints Senior Director of Business Development in Europe

barbara.lempert King of Prussia, PA – Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced the extension of its presence ...

Novartis picks up its development option in $700M rare-disease pact

John Carroll Novartis has picked up its option on a Phase II-ready therapy for a pair of rare disease from Sweden's Camarus, forking over a milestone included in their $ 700 million ...

Medivir ends hep B drug development

Emily Mullin Medivir, which is partnered with Johnson & Johnson on the late-stage hep C drug simeprevir, said it has discontinued the development of its hepatitis B compound MIV-210 ...

Global Ubiquitin Proteasome Research and Development Market to Surpass $5.5 Billion by 2018: BCC Research

mia.burns Wellesley, Mass. – According to a new technical market research report, UBIQUITIN PROTEASOME: GLOBAL MARKETS FOR RESEARCH TOOLS, DIAGNOSTICS AND DRUG DISCOVERY (Report ...

Certara Announces Acquisition of Great Lakes Drug Development

barbara.lempert Certara Announces Acquisition of Great Lakes Drug Development, Inc. Acquisition will further increase the depth of Certara’s early drug development analysis, modeling ...
Page 1 of 41234
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS